May 22, 2020
Tricida nets from the offering approximately $193M
Tricida estimates that the net proceeds from the offering will be approximately $193.0 million
Pharmaceuticals, Biotechnology and Life Sciences
Tag: Tricida
June 25, 2019
Tricida Announces Publication of Positive Long-Term Phase 3 Clinical Trial Results of Veverimer (TRC101) in The Lancet
TRCA-301E trial is the first, long-term, randomized, multicenter, blinded, placebo-controlled trial to evaluate the treatment of metabolic acidosis in patients…
April 8, 2019
Tricida Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Tricida has closed public offering of common stock and full exercise of underwriters’ option to ourchase additional shares
April 4, 2019
Tricida Announces Pricing of Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Tricida, Inc. (Nasdaq: TCDA) today announced the pricing of its public offering of 5,600,000 shares of its…